Results 181 to 190 of about 36,987 (240)
ADGRE2: A Promising Immunotherapeutic Target in Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia
Cancer Medicine, Volume 15, Issue 11, November 2026.ABSTRACT
Acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML) are heterogeneous myeloid malignancies with limited therapeutic options and often poor long‐term prognosis due to persistence of therapy‐resistant leukemic stem cells (LSC).Jennifer Neiss, Lisa Hemetsberger, Carolin Schaefer, Marc Rijksen, Antonia Schwab, Armin Zebisch, Andreas Reinisch, Heinz Sill, Annkristin Heine, Albert Wölfler +9 morewiley +1 more sourceZanubrutinib Combined With Venetoclax for the Treatment of Central Nervous System‐Involved Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Rare Case Report
Cancer Reports, Volume 9, Issue 11, November 2026.ABSTRACT Background
Clinically significant CNS involvement by CLL/SLL is uncommon, diagnostically challenging, and has no established standard treatment. Case
A 61‐year‐old man with previously untreated CLL/SLL was admitted in April 2023 to Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, with rapidly Wei Xie, Yanxue Yin, Jing Wang, Guohui Cui, Lu Zhang +4 morewiley +1 more sourceScalable Arrayed T‐cell CRISPR Screening in Autologous Tumor Co‐cultures to Prioritize Combination Partners for T‐cell Engagers
Current Protocols, Volume 6, Issue 11, November 2026.Abstract
T‐cell‐engaging therapies (TCE) have shown clinical promise in hematologic malignancies, but the T‐cell‐intrinsic determinants of TCE‐mediated cytotoxicity remain incompletely defined. This is in part because functional studies in patient‐derived primary samples have been technically challenging.Keenan Ernste, Qiao Zhang, Oscar Cazares, Kai Lu, Servando Palencia, Katerina Hatzi, Celine Eidenshenk, Zhixiang Tong, Yanwen Jiang, Hyun Yong Jin +9 morewiley +1 more sourceEvaluating the Sensitivity of Airborne eDNA for Detecting Myotis Bats: Recommendations for Sampling Design
Environmental DNA, Volume 8, Issue 6, November‐December 2026.We conducted field trials under high bat density, low bat density, and winter conditions to evaluate the sensitivity of airborne eDNA for detecting Myotis bats. Our findings highlight the potential and current limitations of these methods and provide a foundation for refining sampling strategies.Samantha E. Gidora, Ghassen Chaieb, Caren C. Helbing, Mark Louie D. Lopez, Anna H. Dema, Sarah L. Trilesky, Faith M. Walker, Daniel E. Sanchez, Elizabeth L. Clare, Lauchlan H. Fraser, Cori L. Lausen +10 morewiley +1 more sourceImpact of venetoclax‐based therapies on CLL‐associated autoimmune cytopenias: A retrospective study conducted by ERIC
HemaSphere, Volume 10, Issue 11, November 2026.Abstract
The impact of venetoclax‐based therapies on autoimmune cytopenias (AIC) in patients with chronic lymphocytic leukemia (CLL) is largely unknown. This study aimed to evaluate preexisting and treatment‐emergent AIC in patients with CLL treated with venetoclax, focusing on the differential impact of venetoclax monotherapy versus venetoclax‐based ...Candida Vitale, Thomas Chatzikonstantinou, Christina Papangelou, Francesca Perutelli, Maria Chiara Montalbano, Giulia Bondielli, Elia Boccellato, Salem Alshemmari, Francesco Angotzi, Miguel Arguello‐Tomas, Tomas Arpas, Sandra Bašić‐Kinda, Sotiria Besikli‐Dimou, Łukasz Bołkun, Tomasz Buczek, Aleksandra Butrym, Katherine Chapis, Sofia Chatzileontiadou, Rosa Collado, Raul Cordoba Mascuñano, Lorenzo De Paoli, Marina Deodato, Maria Dimou, David Donaldson, Joanna Drozd‐Sokołowska, Salem Elias, Andrea Ferrario, Alberto Fresa, Anna Maria Frustaci, Rocío García‐Serra, Ajay Gogia, Isabel González‐Gascón‐y‐Marín, Vasko Graklanov, Maria Hryniewiecka, Zhu Huayuan, Elzbieta Iskierka‐Jażdżewska, Paula Jablonowska‐Babij, Ozren Jaksic, Elzbieta Kalicińska, Maria Kislova, Maya Koren‐Michowitz, Epameinondas Koumpis, Zuzana Kubová, Jorge Labrador, Pietro Lauzzana, Shai Levi, Francesca Martini, Mariia Mikhaleva, Eva Minga, Riccardo Moia, Elżbieta Morawiec‐Szymonik, Marta Morawska, Femke V. M. Mulder, Roberta Murru, Jacopo Olivieri, Ewa Paszkiewicz‐Kozik, Lata Rani, Josep Maria Roncero, Wojciech Salamon, Alessandro Sanna, Lydia Scarfò, Tereza Shokralla, Martin Šimkovič, Matevž Škerget, Emil Spasov, Antigoni Tranidou, Jagoda Tryc‐Szponder, Marzia Varettoni, Andrea Visentin, George Vrachiolias, David Waddell, Ewa Wasik‐Szczepanek, Kamil Wdowiak, Mateusz Wilk, Kamil Wiśniewski, Magdalena Witkowska, Mohamed Yassin, Seyma Yıldız, Klaudia Zielonka, Nil Albiol, Jennifer R. Brown, Benedetto Bruno, Mark Catherwood, Anastasia Chatzidimitriou, Michael Doubek, Gianluca Gaidano, Alessandro Gozzetti, Ritu Gupta, Eleftheria Hatzimichael, Yair Herishanu, Krzysztof Jamroziak, Ioannis Kotsianidis, Luca Laurenti, Eugene Nikitin, Maria Papaioannou, Tomáš Papajik, Martin Špaček, Niki Stavroyianni, Josephine M. I. Vos, Tomasz Wróbel, Münci Yağcı, Arnon P. Kater, Matthew Davids, Petra Langerbeins, Kostas Stamatopoulos, Paolo Ghia, Marta Coscia +106 morewiley +1 more sourceDecision‐Making on First‐Line Treatment Alternatives in Chronic Lymphocytic Leukemia: A Multi‐Criteria Decision Analysis to Elicit Stakeholders' Preferences in Italy
Hematological Oncology, Volume 44, Issue 6, November 2026.ABSTRACT
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Western countries. The introduction of targeted therapies has expanded first‐line treatment options, which differ across multiple relevant dimensions, making therapeutic decisions increasingly challenging.Paolo Sportoletti, Felice Bombaci, Chiara Cernetti, Alessandra Di Costanzo, Francesca Fiorentino, Sara Manurita, Andrea Marcellusi, Riccardo Mercati, Massimo Riccaboni, Chiara Vassallo, Antonio Cuneo +10 morewiley +1 more sourceTargeted Protein Degradation: From Molecular Mechanisms to Emerging Therapeutic Strategies
MedComm, Volume 7, Issue 11, November 2026.Graphical overview of targeted protein degradation: mechanisms, molecular determinants, delivery strategies, and therapeutic development. This graphical abstract summarizes the major degradation pathways involved in targeted protein degradation, including the ubiquitin–proteasome system, endocytosis–lysosome pathway, and autophagy‐dependent degradation.Huaijuan Guo, Haishuang Duan, Yang Liu, Kelan Fang, Lujia Xiao, Ling Bai, Xiao Qu, Xuebing Yan, Kun Zhang +8 morewiley +1 more sourceTrends and socio‐economic disparities in chronic lymphocytic leukaemia 2014–2022: An England‐wide cohort study from the UNCOVER group
British Journal of Haematology, Volume 209, Issue 5, Page 2056-2065, November 2026.Summary
To re‐evaluate chronic lymphocytic leukaemia (CLL) epidemiology in the era of modern therapy, data were extracted from the English National Cancer Registration Dataset (NCRD). A total of 34 427 consecutive diagnoses of CLL were recorded (2014–2022), the largest European dataset on record.Temitope Erinfolami, Amelia Fisher, Indrani Karpha, Yeong Lim, Nurunnahar Akter, Toyyib Abdulkareem, Brogan Johnston, Catrin Tudur Smith, Hilary Lindsay, Shaun Bowden, Debbie Yates, Lelia Duley, Renata Walewska, Stella Williams, David Allsup, Nagesh Kalakonda, Mark Bishton, Andrew Pettitt, Nicolas Martinez‐Calle +18 morewiley +1 more sourceWarm autoimmune haemolytic anaemia in Taiwan: A population‐based study of epidemiology, treatment patterns, survival and healthcare utilisation (2017–2022)
British Journal of Haematology, Volume 209, Issue 5, Page 2273-2283, November 2026.Summary
To describe the epidemiology, treatment patterns, overall survival (OS) and healthcare resource use among patients with warm autoimmune haemolytic anaemia (wAIHA) in Taiwan, adult patients with ≥1 diagnosis code for autoimmune haemolytic anaemia (AIHA) with record of wAIHA‐related treatments between 2017 and 2022 were retrospectively identified Hsiao‐Wen Kao, Shu‐Chen Chang, Dae Young Yu, Tse‐Chih Chou, I‐Ching Tsai, Ann Leon, Alexis Krumme, David Bin‐Chia Wu, Chee Jen Chang +8 morewiley +1 more source